Braun Stacey Associates Inc. Has $10.88 Million Stock Position in Insulet Corporation $PODD

Braun Stacey Associates Inc. lowered its holdings in shares of Insulet Corporation (NASDAQ:PODD) by 7.1% during the first quarter, Holdings Channel reports. The firm owned 51,858 shares of the medical instruments supplier’s stock after selling 3,987 shares during the period. Braun Stacey Associates Inc.’s holdings in Insulet were worth $10,882,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Norges Bank bought a new stake in Insulet in the fourth quarter worth $300,794,000. RTW Investments LP bought a new position in Insulet during the fourth quarter valued at about $92,264,000. AQR Capital Management LLC raised its holdings in Insulet by 161.6% during the fourth quarter. AQR Capital Management LLC now owns 459,115 shares of the medical instruments supplier’s stock valued at $130,499,000 after buying an additional 283,643 shares in the last quarter. SG Americas Securities LLC raised its holdings in Insulet by 712.1% during the first quarter. SG Americas Securities LLC now owns 318,848 shares of the medical instruments supplier’s stock valued at $66,907,000 after buying an additional 279,587 shares in the last quarter. Finally, Worldquant Millennium Advisors LLC acquired a new stake in shares of Insulet in the second quarter worth about $80,082,000.

Insiders Place Their Bets

In other Insulet news, Director Timothy C. Stonesifer bought 2,790 shares of the stock in a transaction on Wednesday, June 3rd. The shares were purchased at an average price of $143.51 per share, with a total value of $400,392.90. Following the acquisition, the director directly owned 9,041 shares of the company’s stock, valued at $1,297,473.91. This represents a 44.63% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.36% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. Bank of America decreased their price target on Insulet from $288.00 to $208.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Oppenheimer cut their price objective on Insulet from $300.00 to $210.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. UBS Group set a $219.00 target price on Insulet in a report on Thursday, June 11th. Rothschild & Co Redburn reaffirmed a “neutral” rating and set a $220.00 target price (down from $380.00) on shares of Insulet in a research report on Friday, April 24th. Finally, Piper Sandler decreased their target price on Insulet from $360.00 to $210.00 in a research report on Wednesday, May 6th. Twenty-two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Insulet currently has an average rating of “Moderate Buy” and a consensus price target of $238.67.

Insulet Stock Up 2.9%

PODD stock opened at $158.25 on Friday. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81. Insulet Corporation has a 52-week low of $138.79 and a 52-week high of $354.88. The company has a 50-day moving average of $159.09 and a two-hundred day moving average of $220.64. The stock has a market capitalization of $10.96 billion, a price-to-earnings ratio of 36.80, a price-to-earnings-growth ratio of 1.10 and a beta of 1.13.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.19 by $0.23. The company had revenue of $761.70 million for the quarter, compared to the consensus estimate of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm’s revenue was up 33.9% compared to the same quarter last year. During the same period last year, the business posted $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, equities research analysts anticipate that Insulet Corporation will post 6.46 EPS for the current year.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.